Other Content - Pharmaceutical Executive

ADVERTISEMENT

Other Content
News stories on health policy developments from the Hill and their effect on the pharmaceutical industry

Obama Policies Reshape Pharma Marketing

April 10, 2014

Health reform initiatives promote transparency, challenge reimbursement, writes Jill Wechsler.

Data disclosure, integrity challenge pharma

March 1, 2014

Transparency initiatives are multiplying, affecting research, marketing and compliance.

Drug Coverage, Costs Under Scrutiny

February 1, 2014

Benefits offered by insurance plans on health exchanges and through Medicare are raising concerns about patient access to needed therapies, writes Jill Wechsler.

Pharma Challenges for 2014

January 1, 2014

Pricing and personalized medicine are key themes shaping drug development and marketing

FDA Pursues Delicate Balancing Act

December 1, 2013

The Agency struggles to ensure access to needed medicines while minimizing potential risks, writes Jill Wechsler.

Transparency Troubles for Pharma

November 1, 2013

High prices, murky financial relations, and a reluctance to disclose clinical data undermine public trust in industry and the research enterprise.

Brand-Generic Wars Heat Up

October 1, 2013

Tension mounts over biosimilars, co-pay coupons, trade, and testing.

Biopharma Innovation in Trouble?

September 1, 2013

Rising costs will mean a drop in anticipated NDAs next year, reflecting an ever-longer and more costly drug-development process that is squeezing pharma investment in R&D.

Costs and Coverage Challenge Medicare Drug Plans

August 1, 2013

Rate cuts and fraud concerns create problems for Part D plans and Part B providers.

ADVERTISEMENT

Click here